KoBioLabs, Inc (KOSDAQ:348150)
5,440.00
-510.00 (-8.57%)
At close: Apr 2, 2026
KoBioLabs Revenue
In the year 2025, KoBioLabs had annual revenue of 69.29B KRW with 1.36% growth. KoBioLabs had revenue of 15.12B in the quarter ending December 31, 2025, a decrease of -14.36%.
Revenue
69.29B
Revenue Growth
+1.36%
P/S Ratio
1.67
Revenue / Employee
n/a
Employees
n/a
Market Cap
115.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69.29B | 932.96M | 1.36% |
| Dec 31, 2024 | 68.36B | 35.22B | 106.28% |
| Dec 31, 2023 | 33.14B | 21.53B | 185.54% |
| Dec 31, 2022 | 11.61B | 8.71B | 301.12% |
| Dec 31, 2021 | 2.89B | -1.70B | -36.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 123.77B |
| Cell Biotech | 53.13B |
| CORESTEMCHEMON | 20.13B |
| BIO-FD&C | 18.82B |
| QuadMedicine | 13.11B |
| TegoScience | 5.94B |
| Quratis | 2.46B |
| NovMetaPharma | 1.30B |